ReViral snags $44m Series C
ReViral Ltd., a clinical-stage biopharmaceutical company, has raised $44 million in Series C financing.
26 August 2020•1 min read
ReViral Ltd., a clinical-stage biopharmaceutical company, has raised $44 million in Series C financing.